N/A N=69 Diagnostic

Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19

Covid19

Bottom Line

View on ClinicalTrials.gov: NCT04912895 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2023

Primary outcome: Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: PneumoniaCheck (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Emory University
Primary completion: Aug 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Sensitivity of Detecting SARS-CoV-2 RNA	31; 0	—
PRIMARY Specificity of Detecting SARS-CoV-2 RNA	10; 18	—

Summary

The purpose of this study is to learn how to better detect infection and understand how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes lung disease and is spread. The novel device called PneumoniaCheck is a safe way to collect material from the lung from coughs. Study participants will collect cough specimens over a 24 hour period.

Eligibility Criteria

Inclusion Criteria

Being treated for an acute respiratory illness either as inpatients or outpatients at Emory University Hospital
English is a primary spoken language

Exclusion Criteria

none

Inclusion Criteria for Healthy Volunteers:

Prior registration in an adult participant database and agreed to be contacted for future studies
English is a primary spoken language

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04912895). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.